Interestingly, administration of an HGF-targeting antibody (AMG-102) [17] in experimental models of pancreatic cancer was able to produce a phenotypic reprogramming of stromal cells that ultimately led to decreased collagen deposition [18]. Here, HGF is linked to pancreatic neoplasm.